Running a clinical trial in Canada requires navigating a regulatory framework that is structurally distinct from the United States even though it shares much of the same scientific and ethical foundation. Health Canada, not the FDA, is the authorizing regulator; the Clinical Trial Application (CTA) is Canada’s equivalent to a US Investigational New Drug (IND) application; and no trial can begin without both a Health Canada authorization and a separate Research Ethics Board (REB) approval. This guide walks through that framework for research administrators, sponsors, and site staff working on Canadian trials for the first time.
Who regulates clinical trials in Canada
Health Canada is the federal regulator responsible for authorizing the sale and importation of drugs for use in human clinical trials in Canada. Its authority for clinical trials involving drugs (including biologics) comes from Part C, Division 5 of the Food and Drug Regulations — “Drugs for Clinical Trials Involving Human Subjects” — which has been in force since September 1, 2001. Health Canada’s detailed expectations for sponsors are set out in guidance documents, most notably GUI-0100, which interprets Part C, Division 5 in practice.
This is a useful anchor point for anyone coming from a US-focused regulatory background: where the FDA reviews an IND under 21 CFR Part 312, Health Canada reviews a Clinical Trial Application under Part C, Division 5 of the Food and Drug Regulations. The two frameworks share a common scientific ancestor in the ICH (International Council for Harmonisation) guideline series — both jurisdictions expect trials to be conducted to ICH E6 Good Clinical Practice standards — but the authorization mechanics differ in ways described below.
The Clinical Trial Application (CTA) process
With the exception of Phase IV studies, a sponsor must file a Clinical Trial Application with Health Canada and receive authorization before selling or importing a drug for use in a Canadian clinical trial. The process has two stages:
- Screening. Health Canada first checks that the submission is administratively complete — that all required components (protocol, investigator’s brochure, product information, REB-related attestations, etc.) have been provided. An incomplete submission is not accepted into review.
- Review. Once screened as acceptable, Health Canada issues an acknowledgement letter marking the start of a 30-day default review period, running from the date a complete application is received. This same 30-day default period applies to Clinical Trial Application Amendments (CTA-As) — changes to an already-authorized trial that require Health Canada sign-off before they take effect.
At the end of review, Health Canada issues one of two outcomes:
- A No Objection Letter (NOL) — the application is authorized and the sponsor may proceed (subject to REB approval, below).
- A Not Satisfactory Notice (NSN) — the application is rejected and the trial cannot proceed as submitted.
This is a structurally important difference from the US IND pathway: FDA’s IND review also runs on a 30-day default clock, but that clock works by implied permission — if the FDA has not imposed a clinical hold within 30 days, the sponsor may proceed without receiving an explicit authorization document. Health Canada’s model requires an affirmative authorization: the sponsor cannot proceed on the strength of Health Canada’s silence, only on the strength of a No Objection Letter actually issued.
Research Ethics Board (REB) review and TCPS2
A Health Canada No Objection Letter is necessary but not sufficient to begin a trial. Canadian trials also require approval from a Research Ethics Board (REB) — Canada’s equivalent to the US Institutional Review Board (IRB) — at each participating clinical site, or from a recognized central/multi-site REB covering those sites. Health Canada is explicit that both authorizations, Health Canada’s and the REB’s, must be in place before a trial is initiated; neither substitutes for the other.
REB review in Canada operates under the TCPS2 (Tri-Council Policy Statement) — the joint ethics policy of Canada’s three federal research funding agencies (CIHR, NSERC, and SSHRC) — which sets the ethical principles and review expectations for research involving humans at Canadian institutions, including but not limited to drug trials. An REB assesses informed consent materials and processes, participant risk/benefit balance, privacy and data-handling arrangements, and the ongoing conduct of the study, in a role that maps closely onto what a US IRB does under the Common Rule — for a general treatment of what an ethics board does and doesn’t review, see the site’s IRB/REC approval process guide.
Health Canada vs. FDA: key structural differences
Most of this site’s existing clinical-research content is written from a US regulatory vantage point, so it is worth being explicit about where the Canadian framework diverges rather than assuming a one-to-one mapping:
- Authorization model. FDA’s IND uses a default-permission model (proceed unless FDA objects within 30 days). Health Canada’s CTA uses an affirmative-authorization model (proceed only once a No Objection Letter is actually issued).
- Governing regulation. FDA: 21 CFR Part 312. Health Canada: Food and Drug Regulations, Part C, Division 5, interpreted through guidance documents such as GUI-0100.
- Ethics review is dual and independent either way. A US trial needs both FDA authorization and IRB approval; a Canadian trial needs both a Health Canada No Objection Letter and REB approval. Neither country lets the regulator’s authorization stand in for ethics review, or vice versa.
- Terminology collision to watch for. In US/global clinical-research usage, “CTA” commonly means Clinical Trial Agreement — the contract between sponsor and institution. In the Canadian regulatory context, “CTA” means Clinical Trial Application — the Health Canada submission described in this guide. The same three-letter acronym refers to two unrelated documents; context (and jurisdiction) determines which one is meant.
Clinical trial registration and public disclosure
Health Canada maintains a public Clinical Trials Database, which lists trials that have been authorized by Health Canada since April 1, 2013 — the database is populated with a given trial’s information after Health Canada issues that trial’s No Objection Letter. It is worth being precise about what this database is and isn’t: Health Canada itself describes it as a database of authorized trials rather than a prospective trial registry, so it does not by itself satisfy the kind of pre-enrollment registration expectations that journals and funders increasingly apply (comparable in concept to prospective trial registries like ClinicalTrials.gov in the US).
Separately, Health Canada has issued guidance encouraging sponsors of Health Canada-authorized trials to register with a registry that meets WHO International Clinical Trials Registry Platform (ICTRP) standards — such as ClinicalTrials.gov or ISRCTN — before enrolling the first participant, consistent with international norms around prospective registration. Sponsors and research offices should treat this as separate from, and in addition to, the CTA authorization step itself: authorization from Health Canada does not automatically constitute registration in a WHO-ICTRP-compliant registry, and funder or journal registration requirements should be checked independently. Because registration policy in this area has continued to evolve, confirm the current mandatory/voluntary status directly against Health Canada’s own guidance before relying on a specific requirement.
Practical considerations for research administrators
- Sequence your approvals deliberately. REB and Health Canada review can run in parallel, but trial initiation requires both to have concluded favourably — build institutional timelines around the slower of the two, not just the 30-day Health Canada default.
- Track amendments as their own regulatory event. A Clinical Trial Application Amendment (CTA-A) triggers its own 30-day default review; protocol or product changes made mid-trial cannot be treated as administrative housekeeping if they fall within CTA-A scope.
- Don’t conflate GCP conduct expectations with the authorization step. A No Objection Letter authorizes the trial to begin; ongoing compliance with Good Clinical Practice (GCP) obligations, safety reporting, and REB-approved protocol adherence continues for the life of the study.
- Multi-jurisdiction trials need both pathways mapped separately. A trial running sites in both Canada and the US (or elsewhere) needs a Health Canada CTA for the Canadian sites and a separate IND (or equivalent) for other jurisdictions — one authorization does not substitute for the other, even where the underlying protocol is identical.
Frequently asked questions
Is a Clinical Trial Application required for every trial in Canada?
A CTA is required for Phase I, II, and III drug trials involving human subjects, with Phase IV studies generally exempt from this specific requirement. Device trials and other research types fall under different regulatory pathways.
Can a trial start once Health Canada issues a No Objection Letter?
Not on its own. Trial initiation requires both the Health Canada No Objection Letter and REB approval from the participating site(s) — Health Canada is explicit that both must be in place before a trial begins.
Is Health Canada’s Clinical Trials Database the same as registering a trial?
No. The database is populated by Health Canada itself after a No Objection Letter is issued for authorized trials; it is not a substitute for prospectively registering a trial in a WHO ICTRP-compliant registry such as ClinicalTrials.gov, which funders and journals may separately require.
How does a Research Ethics Board (REB) differ from a US IRB?
Functionally they play the same role — reviewing informed consent, participant risk, and study conduct — but an REB operates under TCPS2, the Tri-Council Policy Statement jointly issued by CIHR, NSERC, and SSHRC, rather than under the US Common Rule that governs IRBs.
For the broader clinical-research regulatory landscape this guide sits within, see the clinical research pillar page.
